Decreasing case fatality in myocardial infarction is explained by improved medical treatment

Karl Andersen1, Bergrós Kristín Jóhannesdóttir, Jón M Kristjánsson

  • 1University of Iceland, Faculty of Medicine, Reykjavik, Iceland. andersen@lsh.is

Acta Cardiologica
|March 31, 2011
PubMed

Insights

Improved medical management, including aspirin, beta-blockers, and reperfusion therapy, significantly reduced one-year mortality for ST-elevation myocardial infarction (STEMI) patients. Increased age and diuretic use were associated with higher mortality rates.

Area of Science:

  • Cardiology
  • Public Health

Background:

  • Treatment strategies for ST-elevation myocardial infarction (STEMI) have evolved over the past 20 years.
  • Understanding the impact of these changes on patient outcomes is crucial.

Purpose of the Study:

  • To investigate the effect of evolving STEMI treatment on one-year mortality.
  • To identify key factors influencing survival rates after STEMI.

Main Methods:

  • Retrospective analysis of all STEMI hospital admissions in Reykjavik, Iceland, for 1986, 1996, and 2006.
  • Cox proportional hazard analysis to determine factors associated with one-year mortality.

Main Results:

  • One-year mortality for STEMI decreased significantly from 26.3% in 1986 to 12.9% in 2006.
  • Aspirin, reperfusion therapy, and beta-blockers at discharge were strongly associated with reduced mortality.
  • Diuretic use and advanced age correlated with increased one-year mortality.

Conclusions:

  • Improved medical management, particularly aspirin, beta-blockers, and reperfusion therapy, has driven the reduction in STEMI one-year mortality.
  • Aggressive reperfusion strategies and appropriate discharge medications are key to improving survival.
  • Congestive heart failure (indicated by diuretic use) and older age remain negative prognostic factors.
Abstract

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...